BioMedPartners (Group)

https://www.biomedvc.com

Based in Basel, Switzerland, BioMedPartners is an independent European venture capital firm that acts as lead-or co-lead investor providing private equity to early-to mid-stage life sciences companies. Since 2002, BioMedPartners has invested in several highly innovative companies of which twenty-two have already either successfully been acquired by leading biopharma companies or have completed an IPO. With more than CHF 350 million in capital under management and a strong team of experienced industry experts as well as an extensive scientific and pharma network, BioMedPartners has established itself as one of the leading early-stage human healthcare investors in Europe. In February 2018, the company announced the closing of BioMedInvest III, their third equity venture capital fund of CHF 100 million. In this third fund BioMedPartners is focusing on the build-up of companies with highly innovative early stage assets and technology platforms. The first investment of BioMedInvest III was in the Swiss immuno-oncology company Amal SA (Geneva) which has been acquired by Boehringer Ingelheim in June 2019. *

	Start	2009-03-13 renamed
	Predecessor	BioMedInvestor (Group)
	Industry	venture capital
	Industry 2	BIOTECH
	Person	Hosang, Markus (BioMedPartners 201108 General Partner)
	Person 2	Fischer, Karsten (Memo Therapeutics 201806–202311 CEO before BioMedPartners + WestLB LEFT 11/23)

	Region	Basel BS
	Country	Switzerland
	Street	23 Elisabethenstr.
	City	4051 Basel BS
	Tel	+41-61-270-3535
		Address record changed: 2022-06-11

Basic data	Employees	n. a.
	Currency	CHF
	Annual sales	350,000,000 (capital under management 2020-10-19)

		* Document for »About Section«: Topas Therapeutics GmbH. (10/19/20). "Press Release: Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing". Hamburg.

		Record changed: 2023-06-26